Viteri, S. (S.)

Filtering

2007 - 200912010 - 20182

Settings

Author search.filters.isAuthorOfPublication.a18abe0d-fb47-4afa-ae94-cc2b4bced9f0

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Carcinoma microcítico de pulmón
    (Ediciones Universidad de Navarra, 2007) Perez-Gracia, J.L. (Jose Luis); Martin-Algarra, S. (Salvador); Lopez-Picazo, J.M. (José M.); Gurpide, A. (Alfonso); Garcia-Foncillas, J. (Jesús); Viteri, S. (S.)
    El cáncer microcítico de pulmón es uno de los tumores sólidos más agresivos, por su rápido crecimiento y por su tendencia a metastatizar desde fases tempranas. Sin embargo, también es uno de los tumores más sensibles a los tratamientos de quimioterapia y radioterapia, con los cuales algunos pacientes con enfermedad limitada pueden sobre- vivir a largo plazo. Estas características han hecho de este tumor un modelo clínico sobre el cual se han probado múltiples estrategias de tratamiento, incluyendo tratamientos concomitantes con quimioterapia y radioterapia, esquemas de quimioterapia alternante o de altas dosis con soporte hematológico o la utilización de radioterapia holocraneal profi láctica. Además en los últimos años el cáncer microcítico de pulmón también se ha empleado como plataforma de desarrollo de tratamientos dirigidos contra dianas específi cas o de inmunoterapia. INGLÉS: Small cell lung cancer is one of the most aggressive solid tumors because of its rapid growth and early tendency to spread to distant organs. Nonetheless, it is also one of the most sensitive tumors to chemotherapy and radiotherapy, which can give patients with limited disease a chance to become long-term survivors. These characteristics have made this tumor a clinical model to explore various treatment strategies, including concomitant chemotherapy and radiotherapy, alternant chemotherapy, high-dose chemotherapy with hematologic support, or use of whole-brain prophylactic radiotherapy. In addition, in recent years, small cell lung cancer has been used as a platform to develop some new targeted therapy agents or immunotherapeutic approaches.
  • Thumbnail Image
    Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    (SAGE Publications, 2018) Rodríguez-Abreu, D. (Delvys); Gonzalez-Cao, M. (María); Perez-Ruiz, E. (Elisabeth); Martin-Algarra, S. (Salvador); Llanos-Gil, M. (Maria) de los; Marquez-Rodas, I. (Iván); Royo, M.A. (María Ángeles); Teixidó, C. (Cristina); Puertolas, T. (Teresa); Drozdowskyj, A. (Ana); Rosell, R. (Rafael); Gimenez-Capitan, A. (Ana); Blanco, R. (Remedios); Karachaliou, N. (Niki); Viteri, S. (S.); Crespo, G. (Guillermo); Aldeguer, E. (Erika); Molina-Vila, M.A. (Miguel Angel)
    Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.
  • Thumbnail Image
    Evaluation of multiple serum markers in advanced melanoma
    (Springer, 2011) Alegre-Martinez, E. (Estibaliz); Gonzalez-Cao, M. (María); Martin-Algarra, S. (Salvador); Arroyo, A. (Ainhoa); Zudaire, M.E. (Maria E.); González, Á. (Álvaro); Viteri, S. (S.); Diaz-Lagares, A. (Ángel)
    The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.